What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?

In the rapidly evolving era of more intensive perioperative therapy, the FLOT-durvalumab combination is quickly becoming the standard for good-performance patients who can tolerate triplet chemotherapy and have no contraindications to immunotherapy.

What to do after recurrence will depend in part on...

Paclitaxel and ramucirumab.